Cargando…

Plasma CHI3L1 in Amyotrophic Lateral Sclerosis: A Potential Differential Diagnostic Biomarker

(1) Background: Motor neuron diseases (MNDs) are fatal neurodegenerative diseases. Biomarkers could help with defining patients’ prognoses and stratifications. Besides neurofilaments, chitinases are a promising family of possible biomarkers which correlate with neuroinflammatory status. We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bombaci, Alessandro, Manera, Umberto, De Marco, Giovanni, Casale, Federico, Salamone, Paolina, Fuda, Giuseppe, Marchese, Giulia, Iazzolino, Barbara, Peotta, Laura, Moglia, Cristina, Calvo, Andrea, Chiò, Adriano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058007/ https://www.ncbi.nlm.nih.gov/pubmed/36983366 http://dx.doi.org/10.3390/jcm12062367

Ejemplares similares

Phenotype Analysis of Fused in Sarcoma Mutations in Amyotrophic Lateral Sclerosis
por: Grassano, Maurizio, et al.
Publicado: (2022)

Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis
por: De Marco, Giovanni, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis patients' quality of life and their caregiver burden during COVID-19 pandemic
por: Bombaci, Alessandro, et al.
Publicado: (2021)

Social cognition deficits in amyotrophic lateral sclerosis: A pilot cross‐sectional population‐based study
por: Palumbo, Francesca, et al.
Publicado: (2022)

Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis
por: Canosa, Antonio, et al.
Publicado: (2020)

GBA variants influence cognitive status in amyotrophic lateral sclerosis
por: Canosa, Antonio, et al.
Publicado: (2022)

Serum chloride as a respiratory failure marker in amyotrophic lateral sclerosis
por: Manera, Umberto, et al.
Publicado: (2023)

G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)
por: Salamone, Paolina, et al.
Publicado: (2020)

The role of peripheral immunity in ALS: a population‐based study
por: Grassano, Maurizio, et al.
Publicado: (2023)

Sensory neuropathy in amyotrophic lateral sclerosis: a systematic review
por: Bombaci, Alessandro, et al.
Publicado: (2023)

Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes
por: Canosa, Antonio, et al.
Publicado: (2022)

The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage
por: Manera, Umberto, et al.
Publicado: (2020)

Deep learning methods to predict amyotrophic lateral sclerosis disease progression
por: Pancotti, Corrado, et al.
Publicado: (2022)

SOMAscan Proteomics Identifies Novel Plasma Proteins in Amyotrophic Lateral Sclerosis Patients
por: Berrone, Elena, et al.
Publicado: (2023)

Role of brain 2-[(18)F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis
por: Canosa, Antonio, et al.
Publicado: (2022)

Clinical and Metabolic Signature of UNC13A rs12608932 Variant in Amyotrophic Lateral Sclerosis
por: Calvo, Andrea, et al.
Publicado: (2022)

Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia
por: Pasetto, Laura, et al.
Publicado: (2021)

Untangling the knot: Lifetime physical exercise and amyotrophic lateral sclerosis
por: Chiò, Adriano, et al.
Publicado: (2021)

Projected increase in amyotrophic lateral sclerosis from 2015 to 2040
por: Arthur, Karissa C., et al.
Publicado: (2016)

The links between diabetes mellitus and amyotrophic lateral sclerosis
por: Vasta, Rosario, et al.
Publicado: (2021)

Brain metabolic changes across King’s stages in amyotrophic lateral sclerosis: a (18)F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study
por: Canosa, Antonio, et al.
Publicado: (2020)

Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis
por: Filareti, Melania, et al.
Publicado: (2017)

Withdrawal of mechanical ventilation in amyotrophic lateral sclerosis patients: a multicenter Italian survey
por: Moglia, Cristina, et al.
Publicado: (2023)

The transcription factor Nurr1 is upregulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice
por: Valsecchi, Valeria, et al.
Publicado: (2020)

Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression
por: Tavazzi, Erica, et al.
Publicado: (2022)

Olfactory dysfunction in amyotrophic lateral sclerosis
por: Viguera, Cristina, et al.
Publicado: (2018)

Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm
por: Elamin, Marwa, et al.
Publicado: (2015)

Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis
por: Pasetto, Laura, et al.
Publicado: (2021)

A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression
por: Zandonà, Alessandro, et al.
Publicado: (2019)

Subtle retinal pathology in amyotrophic lateral sclerosis
por: Ringelstein, Marius, et al.
Publicado: (2014)

Psychiatric disorders prior to amyotrophic lateral sclerosis
por: Turner, Martin R., et al.
Publicado: (2016)

Respiratory training in an individual with amyotrophic lateral sclerosis
por: Tabor, Lauren C., et al.
Publicado: (2016)

Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis
por: Bandres‐Ciga, Sara, et al.
Publicado: (2019)

A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis
por: Marini, Cecilia, et al.
Publicado: (2016)

Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis
por: Marini, Cecilia, et al.
Publicado: (2018)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

Exploring the phenotype of Italian patients with ALS with intermediate ATXN2 polyQ repeats
por: Chio, Adriano, et al.
Publicado: (2022)

TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis
por: Beyer, Léon, et al.
Publicado: (2020)

Exploring the Disease-Associated Microglia State in Amyotrophic Lateral Sclerosis
por: Jauregui, Carlota, et al.
Publicado: (2023)

Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail
por: Bombaci, Alessandro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_46gtdusp21ck2nb7rn9uclstpq